[
    {
        "id": "osp-1731",
        "type": "article-journal",
        "title": "Rituximab Leads to Long Remissions in Patients with Chronic Immune Thrombocytopenia",
        "author": [
            {
                "family": "Al-Habsi",
                "given": "Khalid"
            },
            {
                "family": "Al-Khabori",
                "given": "Murtadha"
            },
            {
                "family": "Al-Muslahi",
                "given": "Muhanna"
            },
            {
                "family": "Pathare",
                "given": "Anil"
            },
            {
                "family": "Al-Farsi",
                "given": "Khalil"
            },
            {
                "family": "Al-Huneini",
                "given": "Mohammed"
            },
            {
                "family": "Al-Lamki",
                "given": "Sulayma"
            },
            {
                "family": "Al Kindi",
                "given": "Salam"
            }
        ],
        "URL": "https://omanscience.com/en/articles/rituximab-leads-to-long-remissions-in-patients-with-chronic-immune-thrombocytopenia",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2015
                ]
            ]
        },
        "container-title": "Oman Medical Journal",
        "DOI": "10.5001/omj.2015.24",
        "publisher": "Oman Medical Specialty Board",
        "ISSN": "1999-768X",
        "abstract": "Objectives: To assess the response rate and duration of response in patients with chronic immune thrombocytopenia (ITP) receiving rituximab. Methods: We retrospectively analyzed 32 consecutive patients with chronic ITP who were treated in two tertiary centers in Oman. Response assessment was based on the American Society of Hematology criteria. Results: Nineteen patients (59%) had an initial response. However, six of the 19 patients lost their response leaving 13 patients with long-lasting remissions. The median age at diagnosis was 25 years (range 14–58). The median time from diagnosis to rituximab therapy was 21 months. The median follow-up after starting rituximab was 26 months. The overall cumulative response rate was 59% (complete response 44%, partial response 15%) and the median time to respond was 30 days with a response rate of 44% at four weeks. In all responders, the cumulative rate of loss of response was 32% with a median time to lose response of 54 months. Conclusions: The use of rituximab in ITP achieves high response rate and long remission duration. Our study was limited by the small sample size and further larger prospective studies are recommended."
    }
]